Olema Q2 2026 net loss $63.2M, cash $461.1M; OPERA-01 enrollment complete

Olema Pharmaceuticals, Inc.

Net loss $63.2M vs $43.8M in Q2 2025; R&D expenses $57.8M vs $43.9M (GAAP).
Cash, equivalents, and marketable securities totaled $461.1M as of June 30, 2026.
Completed enrollment in Phase 3 OPERA-01 (palazestrant monotherapy); top-line data expected Q1 2027.
Announced Bayer collaboration to study OP-3136 plus darolutamide in mCRPC; enrollment starts Q4 2026.
Presented initial Phase 1 data for OP-3136 at ASCO 2026 showing tolerability and anti-tumor activity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.